2012
DOI: 10.1038/skinbio.2012.9
|View full text |Cite
|
Sign up to set email alerts
|

Molecular Therapeutics for Heritable Skin Diseases

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

1
8
0

Year Published

2012
2012
2016
2016

Publication Types

Select...
8
1

Relationship

3
6

Authors

Journals

citations
Cited by 9 publications
(9 citation statements)
references
References 48 publications
1
8
0
Order By: Relevance
“…This observation is consistent with previous demonstrations that mice with β-thalassemia, which have ∼25% level of ABCC6 expression, do not develop mineralization phenotype [20]. These findings have implications for any potential therapy that is aimed to restore ABCC6 expression in the liver of patients with PXE, either through gene therapy, protein replacement, or cell-based therapy approaches [21]. At the same time, it is clear that the expression of Abcc6 in inbred mouse strains can result in varying degrees of mineralization dependent of the diet.…”
Section: Discussionsupporting
confidence: 92%
“…This observation is consistent with previous demonstrations that mice with β-thalassemia, which have ∼25% level of ABCC6 expression, do not develop mineralization phenotype [20]. These findings have implications for any potential therapy that is aimed to restore ABCC6 expression in the liver of patients with PXE, either through gene therapy, protein replacement, or cell-based therapy approaches [21]. At the same time, it is clear that the expression of Abcc6 in inbred mouse strains can result in varying degrees of mineralization dependent of the diet.…”
Section: Discussionsupporting
confidence: 92%
“…Proteins were separated on a NuPage gel (Life Technologies) and transferred to Hybond nitrocellulose membranes (GE Healthcare). The following primary antibodies were used: β-actin (1:1000; Santa Cruz, sc-47778), IFT27 [1:1000; gift of G. Pazour, University of Massachusetts (Keady et al, 2012)], GLI1 (1:250; clone V812, Cell Signaling, 2534S), GLI3 (1:200; R&D Systems, AF3690), IFT25 (1:1000; Proteintech, 15732-1-AP) and IFT140 [1:500 (Uitto, 2012)]. HRP-conjugated secondary antibodies (BD Biosciences), SuperSignal substrates (Thermo Scientific) and CL-XPosure film (Thermo Scientific) were used for detection.…”
Section: Cell Culture and In Vitro Assaysmentioning
confidence: 99%
“…In several countries, mutation analysis is now routinely available, every patient having the right to know his/her own mutation. This development expanded the spectrum of disorders encompassed by the term EB and represents the basis for individualized molecular therapeutic approaches (Cho et al, 2012;Uitto, 2012).…”
Section: Clinical Perspectivementioning
confidence: 99%